Showing 1 - 5 of 5 Digestive System Diseases

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma). Subjects will be treated ... Read more >

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Raquel Araujo

Phone: 713.363.9363

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator:

Phone:

In patients with diabetes and high triglycerides, subjects will be given pemafibrate to help reduce triglycerides level and cardiovascular outcomes. ... Read more >

Status: Enrolling

Investigator: Kirk Heyne

Study Coordinator: Caroline Fitzgerald

Phone: 713.441.3250

The purpose of this study is to investigate nivolumab combined with Debio 1143. The study will focus on subjects with specific solid tumors for whom tumors were previously treated with anti-PD-1/PD-L1 therapy as a single therapy (or when used wi ... Read more >